Recursion Pharmaceuticals, Inc. (RXRX)
RXRXNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$3.81
+0.2900 (+8.24%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $2.37bn
- P/E
- –
- EPS, last 4 quarters
- $-0.9000
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.77 to $5.24
- Average volume
- 24.24m
- Previous close
- $3.52
Analysts
4 coveringHold2 buy, 2 hold, 0 sell
Targets a year out average $6.63, +74.0% from here
Earnings
next estimate $-0.2100Next report
Dec 2025
+25.0%
Mar 2026
+26.7%
Jun 2026
-8.7%
Sep 2026
+8.3%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $35.54m | $6.47m | $7.67m | $18.55m |
| Gross profit | $21.26m | -$6.02m | -$3.82m | $8.51m |
| Operating income | -$108.33m | -$128.50m | -$134.97m | -$123.18m |
| Net income | -$108.12m | -$117.50m | -$131.00m | -$119.04m |
Last four quarters: revenue $68.23m, margin -697.1%, free cash flow -$312.48m
News
8 latest- RXRX Q3 Earnings Call Highlights Clinical Progress and Cash RunwayZacks · 6 days ago
- Recursion (RXRX) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
- What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings CallMarketBeat · 6 days ago
- Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone RevenuesZacks · 7 days ago
- Recursion Pharma Q3 Net Loss Narrows, Reports Positive REC-4881 Data; Advances Pipeline RTTNews · 7 days ago
- Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue EstimatesZacks · Nov 2, 2026
- 1 Big Winner and 1 Loser From the Upcoming Anthropic IPOThe Motley Fool · Oct 31, 2026
- Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for InvestorsZacks · Oct 30, 2026
The company
Recursion (NASDAQ: RXRX) is a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncology, rare disease, neuroscience, immunology, and other therapeutic areas with significant unmet need. Enabling its mission is the Recursion OS, an AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system. Powered by proprietary multimodal data, purpose-built AI models, and bilingual teams fluent in both science and AI, the Recursion OS is designed to translate complex science into medicines that matter - faster, better, and at scale - for patients who are waiting.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- recursion.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.